🇰🇷 Ly-Cov016 in South Korea

Ly-Cov016 (ETESEVIMAB) regulatory status in South Korea.

Marketing authorisation

MFDS

  • Status: likely_approved

Ly-Cov016 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in South Korea

Frequently asked questions

Is Ly-Cov016 approved in South Korea?

Yes. MFDS has authorised it.

Who is the marketing authorisation holder for Ly-Cov016 in South Korea?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.